Vaxcyte Corporate Presentation

110 Significant Unmet Needs Remain Despite SOC Today Resulting in Spectrum of Coverage Driving Adoption of Pneumococcal vaccines Estimated coverage of PCVs based on circulating invasive pneumococcal serotypes. 100 90 Percent Coverage of IPD 1 Data in the US is for 2017, inclusive of those > 5 yrs of age 2Varghese et al. Clin Micro and Infect (2020) 26(4): 512.e1-512.e10 VAX-XP 80 70 VAX-24 60 50 PCV20 40 PCV15 30 20 10 PCV13 0 US Adult Most disease caused by strains above and beyond Prevnar 13Ⓡ, driving need for broader- spectrum PCVS. о

View entire presentation